Company intelligence / Profile preview

Odonate Therapeutics

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~46
Development stage: Phase 3

Overview

Odonate Therapeutics was a pharmaceutical company focused on developing tesetaxel, an orally administered taxane chemotherapy agent for the treatment of metastatic breast cancer. The company discontinued development and began winding down operations in March 2021 after FDA feedback indicated its clinical data package was unlikely to support approval[8].

Therapeutic areas: Oncology
Modalities: Small molecules (specifically taxanes/chemotherapy agents)
Industry: Biotech

Drug pipeline

1 asset

tesetaxel

Discontinued

Beyond the preview

Go deeper on Odonate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Odonate Therapeutics.

Explore the full profile